MYOCET 2 MG
DOXORUBICIN HYDROCHLORIDE : 2 MG · DIN 02245015 · SOPHERION THERAPEUTICS LLC
Health Canada status: DORMANT
What is MYOCET?
MYOCET 2 MG contains DOXORUBICIN HYDROCHLORIDE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02245015, held by SOPHERION THERAPEUTICS LLC, supplied as LIPOSOMES for INTRAVENOUS administration. Health Canada currently lists it as dormant, status dated 07-Sep-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MYOCET used for?
Indicated for the first-line treatment of metastatic breast cancer in combination with cyclophosphamide.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02245015 |
|---|---|
| Brand name | MYOCET |
| Generic / active ingredient | DOXORUBICIN HYDROCHLORIDE : 2 MG |
| Manufacturer | SOPHERION THERAPEUTICS LLC |
| Strength | 2 MG |
| Dosage form | LIPOSOMES |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01DB01 DOXORUBICIN |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 07-Sep-2018 |
| Original market date | 2001-12-21 00:00:00 |
How is it administered?
Recommended initial dose: 60 to 75 mg/m2 in combination with cyclophosphamide (600 mg/m2) every 3 weeks. Administer by IV infusion over 1 hour. Do not give as a bolus.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store carton in refrigerator (2 to 8 °C). Do not freeze. Constituted product stable at room temperature for 8 hours or refrigerator for 72 hours.
How is it supplied?
3-vial system: Vial 1 (50mg Doxorubicin HCl), Vial 2 (Liposomes), Vial 3 (Buffer).
Contraindications
Contraindicated in patients with a history of hypersensitivity to doxorubicin or any of the other constituents of Myocet.
Warnings and precautions
Cardiotoxicity (cumulative dose limit 750 mg/m2), myelosuppression (neutropenia, thrombocytopenia), infusion reactions, and hepatic impairment. Avoid extravasation (irritant).
Is DOXORUBICIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by TEVA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01DB01 DOXORUBICIN. 7 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CAELYX | 2 MG | SUSPENSION | BAXTER CORPORATION | MARKETED | DIN 02238389 |
| DOXORUBICIN | 2 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02410397 |
| DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | 150 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02194473 |
| DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | 50 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02194465 |
| DOXORUBICIN HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02409275 |
| DOXORUBICIN INJECTION, BP | 2 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02381982 |
| TARO-DOXORUBICIN LIPOSOMAL | 2 MG | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02493020 |
| ADRIAMYCIN PFS | 2 MG | SOLUTION | PFIZER CANADA ULC | DORMANT | DIN 02071002 |
| ADRIAMYCIN RDF | 10 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02065657 |
| ADRIAMYCIN RDF | 150 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02069563 |
Who else supplies DOXORUBICIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DOXORUBICIN appears in 108 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.